



MASSACHUSETTS
GENERAL HOSPITAL

PSYCHIATRY ACADEMY

Child & Adolescent Psychopharmacology 2022

Friday-Sunday • March 18-20, 2022

Live-Stream

WELCOME

On behalf of the entire Massachusetts General Hospital Department of Psychiatry, we are proud to welcome you to our conference on Child and Adolescent Psychopharmacology.

Our goal during this conference is to help you provide the best possible care to young patients who suffer from mental health conditions. Our faculty provide a complete update across research developments, assessment tools, barriers to care, and treatment strategies. The agenda is organized into topic-specific modules that include short lectures and Q&A panels. The panels provide the opportunity to ask questions about the content and easily translate evidence into clinical practice.

You have our full attention over the next three days and we will do our very best to help you assess, treat and manage your patients using the latest evidence to inform your decisions.

Enjoy the program!

TARGET AUDIENCE

The target audience for this event is psychiatrists, primary care and family practice physicians, pediatricians, psychologists, nursing professionals, social workers, residents, and other mental health, primary care and pediatric clinicians.

EVALUATION FORMS/CME/CEU CERTIFICATES

Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to the **Evaluation and CME Information** document in this syllabus for more information. We strongly encourage you to complete the evaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link to claim credit is as follows:

www.mghcme.org/child2022

QUESTIONS

Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questions in the chat box on Zoom. Experience has shown that this method is preferable to that of spontaneous questions.

COPYRIGHT

The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department of Psychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotaping are not allowed. Thank you for your cooperation.

CONTACT INFORMATION

For questions or comments, please contact MGH Psychiatry Academy member services at 866-644-7792 or mghcme@mgh.harvard.edu

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. Recognize the presentation, diagnosis, and current treatment options available for attention deficit and hyperactivity in childhood and adolescence.
2. Identify the presentation, diagnosis, and current treatment options available for behavioral problems and pervasive developmental disorders.
3. Discuss the presentation, diagnosis, and current treatment options available for depression, psychosis, manic depression, and anxiety.
4. Compare and contrast basic neuropharmacology, neuropsychologic testing data, psychopharmacologic properties of compounds, and the implications of psychiatric genetics for guiding day-to-day pediatric psychopharmacology treatment.
5. Recognize the risk management issues associated with adolescent substance use disorder and smoking, ethical and safe use of psychotropics, suicide risk and prevention, cardiovascular side effects and medical liability of stimulants, and liability prevention in psychopharmacology.
6. Review the comorbidity of ADHD with posttraumatic stress disorder and traumatic brain injury.
7. Explore emotional dysregulation, executive function and learning disorders in the context of ADHD.
8. Describe the relationship between antidepressants and suicide risk.
9. Discuss the available naturopathic treatments for emotional dysregulation in youth, including pros, cons, and available evidence.
10. Examine the evidence base for the Pediatric Autoimmune Neurological Disorder Associated with Streptococcus symptoms and its relation to OCD.
11. Describe the presentation, diagnosis, and current treatment options available for childhood onset schizophrenia.
12. Compare and contrast psychotherapeutic treatment approaches for children including DBT, CBT, and others.
13. Explore how animal models provide insight into child and adolescent psychiatric conditions, using ADHD as a model system.
14. Compare and contrast emotional dysregulation from mania, including presentation, course, and treatment.
15. Examine the relationship between learning disorders and ADHD.
16. Describe adult ADHD and discuss the controversies surrounding its diagnosis and treatment.
17. Examine the legal issues involved in treating individuals with ADHD and related disorders.
18. Describe the problems associated with treatment non-adherence and provide strategies to improve adherence in the clinical setting.

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.

McLean Hospital designates this live activity for a maximum of **17.50 *AMA PRA Category 1 Credits***[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for **17.50** Continuing Education (CE) credits for psychologists.

REGISTERED NURSES

This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for **17.50** contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS

This program has been approved for 17.50 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. NASW-MA Chapter CE Approving Program, Authorization Number D 90787-2.

AMERICAN ACADEMY OF FAMILY PHYSICIANS (AAFP)

An application to the AAFP has been submitted and is under review. Please check with mghcme@mgh.harvard.edu for the status of the AAFP application.

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY

THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE *CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY 2022* AND HAS APPROVED THIS PROGRAM AS A PART OF A COMPREHENSIVE *CONTINUING MEDICAL EDUCATION* ACTIVITY, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF CONTINUING CERTIFICATION.

This program is an ABPN-Approved CME activity. It awards up to 17.50 Category 1 CME credits.

Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of *AMA PRA Category 1 Credits*[™] associated with the activity. Providers should check with their regulatory agencies to determine ways in which *AMA PRA Category 1 Credits*[™] may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.

AGENDA

FRIDAY, MARCH 18, 2022

8:00 – 8:10 AM **Introduction**
Joseph Biederman, MD, Timothy E. Wilens, MD, David H. Rubin, MD

MODULE TOPIC: OVERVIEW OF PEDIATRIC PSYCHOPHARMACOLOGY

8:10 – 8:30 AM **Diagnosis & Assessment in Pediatric Psychopharmacology**
Joseph Biederman, MD

8:30 – 8:50 AM **Implications of Psychiatric Genetics for Psychopharmacology**
Stephen V. Faraone, PhD

8:50 – 9:10 AM **Question & Answer Panel**
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD & Stephen V. Faraone, PhD

MODULE TOPIC: ADHD AND SUBSTANCE USE DISORDERS

9:10 – 10:00 AM **ADHD and its Treatment Across the Life Cycle**
Joseph Biederman, MD

10:00 – 10:20 AM **Substance Use Disorders: Part I**
Timothy E. Wilens, MD

10:20 – 10:40 AM **Substance Use Disorders: Part II**
Timothy E. Wilens, MD

10:40 – 11:10 PM **Question & Answer Panel**
Moderator: David H. Rubin, MD
Panelists: Joseph Biederman, MD & Timothy E. Wilens, MD

11:10 – 12:10 PM **Break**

MODULE TOPIC: MOOD DISORDERS AND EMOTIONAL DYSREGULATION

12:10 – 12:30 PM **Juvenile Depression**
David H. Rubin, MD

12:30 – 12:50 PM **Illuminating the Black Box: Antidepressants, Youth and Suicide**
David H. Rubin, MD

12:50 – 1:10 PM **Juvenile Mania**
Janet Wozniak, MD

1:10 – 1:30 PM **Differentiating Unipolar vs. Bipolar Mood Disorders in the Young**
Janet Wozniak, MD

1:30 – 1:50 PM **Schizophrenia & Pharmacological Approaches to Pediatric Mania**
Janet Wozniak, MD

1:50 – 2:05 PM **Break**

- 2:05 – 2:25 PM **Distinguishing Emotional Dysregulation from Mania**
Joseph Biederman, MD
- 2:25 – 2:55 PM **Question & Answer Panel**
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD, Janet Wozniak, MD & David H. Rubin, MD
- 2:55 – 3:55 PM **Ask the Experts**
Moderator: David H. Rubin, MD
Joseph Biederman, MD, Timothy E. Wilens, MD, Janet Wozniak, MD
- 3:55 PM **Adjourn**

SATURDAY, MARCH 19, 2022

- 8:00 – 8:05 AM **Introduction**
Joseph Biederman, MD

MODULE TOPIC: OCD, ANXIETY DISORDERS, TOURETTE'S, PANDAS AND ASD TRAITS

- 8:05 – 8:25 AM **Tourette's Disorder & Tics**
Erica Greenberg, MD
- 8:25 – 8:45 PM **Obsessive Compulsive Disorder**
Erica Greenberg, MD
- 8:45 – 9:05 AM **PANDAS**
Erica Greenberg, MD
- 9:05 – 9:25 AM **Pediatric Anxiety Disorders**
Erica Greenberg, MD
- 9:25 – 9:45 AM **Are Autistic Traits Clinically Meaningful?**
Joseph Biederman, MD
- 9:45 – 10:15 AM **Question & Answer Panel**
Moderator: Joseph Biederman, MD
Panelist: Erica Greenberg, MD
- 10:15 – 10:30 AM **Break**

MODULE TOPIC: PSYCHOLOGICAL ASSESSMENT & INTERVENTION

- 10:30 – 10:50 AM **Cognitive Behavioral Treatment for Young Adults: Education & Psychological Testing**
Aude Henin, PhD
- 10:50 – 11:10 AM **Cognitive Behavioral Therapy for Anxiety in Young Children**
Aude Henin, PhD

- 11:10 – 11:30 PM **Using Psychological Assessment to Inform Treatment**
Aude Henin, PhD
- 11:30 – 12:00 PM **Question & Answer Panel**
Moderator: Joseph Biederman, MD
Panelists: Erica Greenberg, MD, Aude Henin, PhD
- 12:00 PM **Adjourn**

SUNDAY, MARCH 20, 2022 ADHD DAY

- 8:00 – 8:05 AM **Introduction**
Joseph Biederman, MD, Timothy E. Wilens, MD

MODULE TOPIC: DIAGNOSIS AND UNDERPINNINGS OF ADHD

- 8:05 – 8:25 AM **Definitions and Overview of ADHD**
Joseph Biederman, MD
- 8:25 – 8:45 AM **Genetics of ADHD**
Stephen V. Faraone, PhD
- 8:45 – 9:05 AM **Neuroimaging and ADHD**
Susan Whitfield-Gabrieli, PhD
- 9:05 – 9:25 AM **Diagnosis of Adult ADHD**
Thomas Spencer, MD
- 9:25 – 9:55 AM **Question & Answer Panel**
Moderator: Timothy E. Wilens, MD
Panelists: Stephen V. Faraone, PhD, Joseph Biederman, MD, Susan Whitfield-Gabrieli, PhD, Thomas Spencer, MD
- 9:55 – 10:10 AM **Break**

MODULE TOPIC: TREATMENT OF ADHD

- 10:10 – 10:30 AM **Treatment of ADHD with Stimulants I Pediatrics**
Thomas Spencer, MD
- 10:30 – 10:50 AM **Treatment of ADHD with Stimulants II Adults**
Thomas Spencer, MD
- 10:50 – 11:10 AM **Pharmacological Treatment of ADHD Across the Life Span: Nonstimulants**
Timothy E. Wilens, MD
- 11:10 -11:30 AM **The Serious Problem of Non-Adherence to Treatment in ADHD and Ways to Mitigate it**
Joseph Biederman, MD

11:30 – 12:00 PM **Question & Answer Panel**
Moderator: Stephen V. Faraone, PhD
Panelists: Joseph Biederman, MD & Timothy E. Wilens, MD, Thomas Spencer, MD

12:00 – 1:00 PM **Break**

MODULE TOPIC: EMOTIONAL DYSREGULATION, EXECUTIVE FUNCTION AND LEARNING DISORDERS

1:00 – 1:20 PM **CBT & Psychosocial Treatments in ADHD**
Aude Henin, PhD

1:20 – 1:40 PM **ADHD & Education**
Aude Henin, PhD

1:40 – 2:00 PM **Functional Outcomes in ADHD and the Critical Importance of Treatment to Mitigate Them**
Joseph Biederman, MD

2:00 – 2:30 PM **Question & Answer Panel**
Moderator: Timothy E. Wilens, MD
Panelists: Joseph Biederman, MD & Aude Henin, PhD

2:30 – 2:45 PM **Break**

MODULE TOPIC: ADDRESSING COMORBIDITIES OF ADHD

2:45 – 3:05 PM **ADHD, Tics and Tourette's Disorder**
Erica Greenberg, MD

3:05 – 3:25 PM **Comorbidity of ADHD with Substance Use Disorders and Associated Risk Management Issues**
Timothy E. Wilens, MD

3:25 – 3:45 PM **Management of ADHD in the Context of Autism Spectrum Disorders**
Joseph Biederman, MD

3:45 – 4:05 PM **ADHD, PTSD & TBI**
Joseph Biederman, MD

4:05 – 4:35 PM **Question & Answer Panel**
Moderator: Joseph Biederman, MD
Panelists: Erica Greenberg, MD, & Timothy E. Wilens, MD

4:35 PM **Adjourn**

FACULTY

PLANNERS & COURSE DIRECTORS

Joseph Biederman, MD (Course Director)

Chief, Clinical and Research Programs
in Pediatric Psychopharmacology and Adult ADHD
Director, Bressler Program for Autism Spectrum Disorder
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

David H. Rubin, MD (Course Director & Reviewer)

Director, Child and Adolescent Psychiatry Residency Training
Massachusetts General Hospital and McLean Hospital
Director, Postgraduate Medical Education, Department of Psychiatry
Executive Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Thomas J. Spencer, MD (Course Director)

Associate Professor of Psychiatry
Harvard Medical School
Associate Chief, Clinical and Research Program
Pediatric Psychopharmacology

Timothy E. Wilens, MD (Course Director)

Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Jane Pimental, MPH

Managing Director
Massachusetts General Hospital Psychiatry Academy

Susan Sprich, PhD (Psychologist Reviewer)

Director, Postgraduate Psychology Education
Director, Cognitive Behavioral Therapy Program
Massachusetts General Hospital
Assistant Professor of Psychology
Harvard Medical School

SPEAKERS

Joseph Biederman, MD (Course Director)

Chief, Clinical and Research Programs

in Pediatric Psychopharmacology and Adult ADHD
Director, Bressler Program for Autism Spectrum Disorder
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Stephen V. Faraone, PhD

Distinguished Professor of Psychiatry and of
Neuroscience & Physiology
SUNY Upstate Medical University

Susan Whitfield-Gabrieli, PhD

Professor of Psychology
Founding Director of the Northeastern University Biomedical Imaging Center (NUBIC)
Northeastern University
McGovern Institute for Brain Research Affiliate
MIT
Consultant, Department of Psychiatry, MGH

Erica Greenberg, MD

Director, Pediatric Psychiatry OCD and
Tic Disorders Program
Psychiatrist
Massachusetts General Hospital
Instructor
Harvard Medical School

Aude Henin, PhD

Co-Director, Child Cognitive-Behavioral Therapy Program
Department of Psychiatry
Massachusetts General Hospital
Assistant Professor of Psychology
Harvard Medical School

David H. Rubin, MD (Course Director & Reviewer)

Director, Child and Adolescent Psychiatry Residency Training
Massachusetts General Hospital and McLean Hospital
Director, Postgraduate Medical Education, Department of Psychiatry
Executive Director, Massachusetts General Hospital Psychiatry Academy
Massachusetts General Hospital

Thomas J. Spencer, MD (Course Director)

Associate Professor of Psychiatry
Harvard Medical School
Associate Chief, Clinical and Research Program
Pediatric Psychopharmacology

Timothy E. Wilens, MD (Course Director)

Chief, Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Janet Wozniak, MD

Chair, Quality and Safety, Department of Psychiatry
Director, Child and Adolescent Psychiatry Outpatient Service
Director, Pediatric Bipolar Disorder Clinical and Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School

DISCLOSURE INFORMATION

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all financial relationships with ineligible companies for the past 24 months, as defined below:

Ineligible Companies

The ACCME defines an “Ineligible company” as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” For more information, visit accme.org/standards

Financial relationships

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected.

Mitigation of Financial Relationships

All financial relationships are reviewed to determine which ones are relevant, and then measures are taken to mitigate all relevant financial relationships and ensure that they do not insert commercial bias into the content of the education.

The following planners, speakers, content reviewers, and others in control of educational content have reported financial relationships with ineligible companies over the past 24 months. Measures have been taken to mitigate the impact of these financial relationships on the educational content and ensure that they do not insert commercial bias into the content of this education.

Speakers & Planners:

Joseph Biederman, MD

Royalties (ADHD Diagnosis): Biomarin, Bracket Global, Cogstate, Ingenix, Medavent Prophase, Shire/Takeda, Sunovion, and Theravance

Partnership(commercialize a digital health intervention to improve adherence in ADHD): MEMOTEXT

Research Support: Genentech, Headspace Inc., Pfizer Pharmaceuticals, Roche TCRC Inc., Sunovion Pharmaceuticals Inc., Takeda/Shire Pharmaceuticals Inc., and Tris

Honorarium (Scientific Presentation): Tris

Stephen Faraone, PhD

Research Grants/CME Grant Support/Consulting: Otsuka

Research Grants/CME Grant Support: Sunovion

Research Grants/Advisory Board: Supernus

CME Grant Support: Shire/Takeda

Consulting: Akili Interactive Labs, Aardvark, Aveksham, Enzymotec, Ironshore, Noven, Rhodes, Tris, and Vallon

Consulting/Advisory Board: Arbor, Ondosis, KemPharm/Corium

Consulting/Advisory Board/Stock: Genomind

US Patent: A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD

Royalties: Elsevier, Guilford Press, Oxford University Press

Erica Greenberg, MD

Speaker: MGH Psychiatry Academy, Psychiatry Education Forum

Speaker (Advisory Board): Tourette Association of America

Aude Henin, PhD

Royalties: Oxford University Press

Thomas Spencer, MD

Consultant (MGH Advisor): Avekshan

Research Support(MGH PI): The FDA; Department of Defense

Royalties (MGH Corporate Sponsored): ADHD Scales Royalty Licensing

Non-Stimulant Treatment for ADHD (no license fees): US patent (#61/233,686)

Stimulant Abuse Prevention (no license fees): US patent (#61/233,686)

Susan Sprich, PhD

Royalties: Oxford University Press; Springer

Honorarium (associate editor of a journal): Association for Behavioral and Cognitive Therapies

Timothy E. Wilens, MD

Principal Investigator (Grant/Research Support): NIH (NIDA)

Consultant: Arbor Pharmaceuticals; Otsuka; KemPharm; Ironshore; Vallon

Intellectual Property (Licensing Agreement): Ironshore

Intellectual Property (Published book): Guilford Press

Intellectual Property (Co/edited textbook): Cambridge University Press

Clinical Consulting: Gavin Foundation; Bay Cove Human Services; US National Football League (ERM Associates); US Minor/Major League Baseball

Consultant (Shared IP): White Rhino/3D

Janet Wozniak, MD

Research Support: Johnson and Johnson; Pfizer

Author: Bantam Books

Consultation Fees (Spouse): Emalex; Noctrix; CVS

All other individuals in a position to control the content of this educational activity have reported no financial relationships with ineligible companies.